154,427 Shares in Bristol Myers Squibb Company $BMY Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the first quarter, Holdings Channel reports. The firm purchased 154,427 shares of the biopharmaceutical company’s stock, valued at approximately $9,366,000.

Several other institutional investors also recently bought and sold shares of BMY. Kentucky Retirement Systems increased its holdings in Bristol Myers Squibb by 6.2% in the 1st quarter. Kentucky Retirement Systems now owns 135,941 shares of the biopharmaceutical company’s stock worth $8,245,000 after acquiring an additional 7,988 shares in the last quarter. Centaurus Financial Inc. grew its position in shares of Bristol Myers Squibb by 95.4% in the first quarter. Centaurus Financial Inc. now owns 19,494 shares of the biopharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 9,516 shares during the period. Bull Harbor Capital LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at about $3,719,000. Strategic Investment Advisors MI purchased a new stake in shares of Bristol Myers Squibb during the first quarter worth about $101,000. Finally, Arkadios Wealth Advisors raised its position in shares of Bristol Myers Squibb by 2.9% during the 1st quarter. Arkadios Wealth Advisors now owns 299,224 shares of the biopharmaceutical company’s stock worth $18,148,000 after purchasing an additional 8,363 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $61.25.

Bristol Myers Squibb Stock Down 0.6%

NYSE BMY opened at $63.24 on Thursday. The business’s fifty day simple moving average is $57.79 and its 200-day simple moving average is $58.22. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a market cap of $129.14 billion, a PE ratio of 17.76, a P/E/G ratio of 0.18 and a beta of 0.23. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $64.96.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.